Marksans Pharma Limited has informed the Exchange regarding a press release dated August 12, 2025, titled "Q1FY26 Financial Results Marksans Pharma ₹620 Cr Revenue in Q1 FY26, up 5% YoY; Strong Cash Position of ₹711 Cr Supports Growth Initiatives".
MARKSANS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Marksans Pharma reported Q1FY26 revenue of ₹620 Cr, up 5% YoY but down 12.5% QoQ. US & North America led growth at ₹327.6 Cr (+30.6% YoY), driven by new launches in gastrointestinal, pain, and digestive health segments, while UK & Europe fell 19% YoY to ₹203.8 Cr and Australia/NZ declined 13.1%. Gross profit rose 8.9% to ₹358.2 Cr with margin expanding 209 bps to 57.8% on lower input costs. However, EBITDA fell 22% YoY to ₹100.1 Cr (margin 16.1%) and PAT dropped 34.7% to ₹58.2 Cr, hit by ramp-up costs, a one-time ECL provision for emerging markets, and forex adjustments. Cash balance remained strong at ₹711 Cr, with ₹48.7 Cr in operating cash flow and ₹37.8 Cr in capex during the quarter.
Mixed quarter for shareholders – top-line growth and robust cash position support the growth story, but sharp YoY decline in EBITDA and profit margins on one-time and ramp-up costs may weigh on near-term sentiment. The market will look for evidence of margin recovery and UK/Australia demand stabilization in the coming quarters.